“Glenmark partners with Pfizer to launch Abrocitinib in India”

Bengaluru, February 1, 2024: Pfizer and Glenmark Pharmaceuticals Ltd. (Glenmark) have joined hands to launch abrocitinib, a first-of-its-kind oral advanced systemic treatment for moderate-to-severe atopic dermatitis (AD), in India. Developed by Pfizer, abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India and is approved by the U.S. Food and Drug Administration (FDA), European Medicines

Read more